Geographic and clinical variation in Clozapine use in the United States

Psychiatric Services

Volumn 65, Issue 2, 2014, Pages 186-192

  Stroup, T Scott ^a   Gerhard, Tobias ^b   Crystal, Stephen ^b   Huang, Cecelia ^b   Olfson, Mark ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE DISPARITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MIDDLE AGED; OUTPATIENT CARE; PSYCHOPHARMACOTHERAPY; RACE DIFFERENCE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; UNITED STATES; YOUNG ADULT; ADOLESCENT; CLINICAL PRACTICE; INSURANCE; MEDICAID; PRESCRIPTION; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84893710941     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300180     Document Type: Article

References (32)

1. Mistry H, Osborn D: Underuse of clozapine in treatment-resistant schizophrenia. Advances in Psychiatric Treatment 17: 250-255, 2011
2. Manuel JI, Essock SM, Wu Y, et al: Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatric Services 63:1146-1149, 2012
3. Tandon R: Antipsychotics in the treatment of schizophrenia: an overview. Journal of Clinical Psychiatry 72(suppl 1):4-8, 2011
4. Leucht S, Corves C, Arbter D, et al: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 373:31-41, 2009
5. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163:600-610, 2006
6. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789-796, 1988
7. Wahlbeck K, Cheine M, Essali A, et al: Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry 156:990-999, 1999
8. Moore TA, Buchanan RW, Buckley PF, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatry 68:1751-1762, 2007
9. Effectiveness NIfHaC: Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care: NICE Clinical Guideline 1. London, National Institute for Health and Clinical Effectiveness, 2002
10. Meltzer HY, Alphs L, Green AI, et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60:82-91, 2003
11. Citrome L, Volavka J, Czobor P, et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services 52:1510-1514, 2001
12. Volavka J, Czobor P, Nolan K, et al: Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Journal of Clinical Psychopharmacology 24:225-228, 2004
13. Copeland LA, Zeber JE, Valenstein M, et al: Racial disparity in the use of atypical antipsychotic medications among veterans. American Journal of Psychiatry 160: 1817-1822, 2003
14. Downs J, Zinkler M: Clozapine: national review of postcode prescribing. Psychiatrist 31:384-387, 2007
15. Bureau of Health Professions: Area Resource File (ARF) system; in US Health Resources and Services Administration. Fairfax, Va, Quality Resource Systems, 2006
16. Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biological Psychiatry 50:898-911, 2001
17. Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 159:567-572, 2002
18. Hsieh MM, Everhart JE, Byrd-Holt DD, et al: Prevalence of neutropenia in the US population: age, sex, smoking status, and ethnic differences. Annals of Internal Medicine 146:486-492, 2007
19. Rajagopal S: Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgraduate Medical Journal 81:545-546, 2005
20. Kasckow J, Ingram E, Brown C, et al: Differences in treatment attitudes between depressed African-American and Caucasian veterans in primary care. Psychiatric Services 62:426-429, 2011
21. Givens JL, Houston TK, Van Voorhees BW, et al: Ethnicity and preferences for depression treatment. General Hospital Psychiatry 29:182-191, 2007
22. Valenstein M, McCarthy JF, Ignacio RV, et al: Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatric Services 57:70-76, 2006
23. Grossman LS, Harrow M, Rosen C, et al: Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. Psychiatric Services 57:844-850, 2006
24. Goldstein JM: Gender differences in the course of schizophrenia. American Journal of Psychiatry 145:684-689, 1988
25. Brunette MF, Drake RE, Xie H, et al: Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin 32:637-643, 2006
26. Mueser KT, Noordsdy DL, Drake RE, et al: Integrated Treatment for Dual Disorders: A Guide to Effective Practice. New York, Guilford, 2003
27. Nejad SH, Gandhi RT, Freudenreich O: Clozapine use in HIV-infected schizophrenia patients: a case-based discussion and review. Psychosomatics 50:626-632, 2009
28. Shrank WH, Choudhry NK, Fischer MA, et al: The epidemiology of prescriptions abandoned at the pharmacy. Annals of Internal Medicine 153:633-640, 2010
29. Pereira S, Beer D, Paton C: Enforcing treatment with clozapine: survey of views and practice. Psychiatric Bulletin 23:342-345, 1999
30. Khaykin E, Eaton WW, Ford DE, et al: Health insurance coverage among persons with schizophrenia in the United States. Psychiatric Services 61:830-834, 2010
31. Davis D, O'Brien MA, Freemantle N, et al: Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 282:867-874, 1999
32. Davis D, Evans M, Jadad A, et al: The case for knowledge translation: shortening the journey from evidence to effect. BMJ (Clinical Research Ed) 327:33-35, 2003